• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

吗啡啉作为药物化学中的一种骨架:合成策略的最新进展。

Morpholine As a Scaffold in Medicinal Chemistry: An Update on Synthetic Strategies.

机构信息

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, National and Kapodistrian University of Athens, 15771, Athens, Greece.

出版信息

ChemMedChem. 2020 Mar 5;15(5):392-403. doi: 10.1002/cmdc.201900682. Epub 2020 Feb 12.

DOI:10.1002/cmdc.201900682
PMID:32017384
Abstract

Morpholine is a frequently used heterocycle in medicinal chemistry and a privileged structural component of bioactive molecules. This is mainly due to its contribution to a plethora of biological activities as well as to an improved pharmacokinetic profile of such bioactive molecules. The synthesis of morpholines is a subject of much study due to their biological and pharmacological importance, with the last such review being published in 2013. Here, an overview of the main approaches toward morpholine synthesis or functionalization is presented, emphasizing on novel work which has not been reviewed so far. This review is an update on synthetic strategies leading to easily accessible libraries of bioactives which are of interest for drug discovery projects.

摘要

吗啡啉是药物化学中常用的杂环,也是生物活性分子的特权结构组成部分。这主要是由于其对多种生物活性的贡献,以及对这些生物活性分子的药代动力学特性的改善。由于吗啡啉的生物学和药理学重要性,它们的合成一直是一个研究热点,最后一次综述发表于 2013 年。本文概述了吗啡啉合成或功能化的主要方法,重点介绍了迄今尚未综述的新工作。本文综述了合成策略,这些策略可以得到易于获得的生物活性文库,这些文库对药物发现项目有意义。

相似文献

1
Morpholine As a Scaffold in Medicinal Chemistry: An Update on Synthetic Strategies.吗啡啉作为药物化学中的一种骨架:合成策略的最新进展。
ChemMedChem. 2020 Mar 5;15(5):392-403. doi: 10.1002/cmdc.201900682. Epub 2020 Feb 12.
2
Morpholine as a privileged structure: A review on the medicinal chemistry and pharmacological activity of morpholine containing bioactive molecules.吗啡啉作为一种特权结构:吗啡啉含生物活性分子的药物化学和药理学活性综述。
Med Res Rev. 2020 Mar;40(2):709-752. doi: 10.1002/med.21634. Epub 2019 Sep 12.
3
Morpholine as ubiquitous pharmacophore in medicinal chemistry: Deep insight into the structure-activity relationship (SAR).吗啡啉作为药物化学中无处不在的药效团:对结构-活性关系(SAR)的深入洞察。
Bioorg Chem. 2020 Mar;96:103578. doi: 10.1016/j.bioorg.2020.103578. Epub 2020 Jan 11.
4
Expanding Complex Morpholines Using Systematic Chemical Diversity.利用系统化学多样性拓展复杂吗啡啉。
Org Lett. 2024 May 3;26(17):3493-3497. doi: 10.1021/acs.orglett.4c00528. Epub 2024 Mar 20.
5
Design and synthesis of reboxetine analogs morpholine derivatives as selective norepinephrine reuptake inhibitors.作为选择性去甲肾上腺素再摄取抑制剂的瑞波西汀类似物吗啉衍生物的设计与合成。
Bioorg Med Chem Lett. 2008 Oct 15;18(20):5550-3. doi: 10.1016/j.bmcl.2008.09.007. Epub 2008 Sep 6.
6
De Novo Assembly of Highly Substituted Morpholines and Piperazines.从头开始组装高度取代的吗啡啉和哌嗪。
Org Lett. 2017 Feb 3;19(3):642-645. doi: 10.1021/acs.orglett.6b03807. Epub 2017 Jan 19.
7
The emergence of the C-H functionalization strategy in medicinal chemistry and drug discovery.药物化学和药物发现中 C-H 功能化策略的出现。
Chem Commun (Camb). 2021 Oct 19;57(83):10842-10866. doi: 10.1039/d1cc04083a.
8
Solid phase organic synthesis (SPOS): a novel route to diketopiperazines and diketomorpholines.固相有机合成(SPOS):一种合成二酮哌嗪和二酮吗啉的新途径。
Mol Divers. 1996 Feb;1(2):125-34. doi: 10.1007/BF01721328.
9
Asymmetric Synthesis of Chiral 1,2-Amino Alcohols and Morpholin-2-ones from Arylglyoxals.芳基乙二醛的手性 1,2-氨基醇和吗啉-2-酮的不对称合成。
J Org Chem. 2018 Sep 7;83(17):10487-10500. doi: 10.1021/acs.joc.8b01516. Epub 2018 Aug 6.
10
Click chemistry inspired synthesis of morpholine-fused triazoles.点击化学启发下的吗啉稠合三唑的合成
J Org Chem. 2014 Jun 20;79(12):5752-62. doi: 10.1021/jo500890w. Epub 2014 Jun 3.

引用本文的文献

1
Design, synthesis, studies and antiproliferative evaluation of some novel hybrids of pyrimidine-morpholine.嘧啶 - 吗啉一些新型杂化物的设计、合成、研究及抗增殖活性评价
Front Chem. 2025 Feb 28;13:1537261. doi: 10.3389/fchem.2025.1537261. eCollection 2025.
2
Design, synthesis and evaluations of new cyclotriphosphazenes as safe drug candidates.新型环三磷腈作为安全候选药物的设计、合成与评价
RSC Med Chem. 2025 Feb 12. doi: 10.1039/d4md00885e.
3
Short Scalable Route to Bis-morpholine Spiroacetals and Oxazepane Analogues: Useful 3D-Scaffolds for Compound Library Assembly.
双吗啉螺缩醛和氧杂氮杂环庚烷类似物的短程可扩展合成路线:用于化合物库组装的有用三维支架
J Org Chem. 2025 Feb 21;90(7):2652-2661. doi: 10.1021/acs.joc.4c02690. Epub 2025 Feb 10.
4
Synthesis and Evaluation of Antibacterial and Antifungal Activities and of Novel Morpholinoalkoxychalcones.新型吗啉代烷氧基查耳酮的抗菌和抗真菌活性的合成与评价
Med Chem. 2025;21(1):61-68. doi: 10.2174/0115734064316022240801093905.
5
Asymmetric imidazole-4,5-dicarboxamide derivatives as SARS-CoV-2 main protease inhibitors: design, synthesis and biological evaluation.作为严重急性呼吸综合征冠状病毒2主要蛋白酶抑制剂的不对称咪唑-4,5-二甲酰胺衍生物:设计、合成及生物学评价
RSC Med Chem. 2024 Sep 3;15(11):3880-8. doi: 10.1039/d4md00414k.
6
C-Alkylation of Imidazo[1,2-a]pyridines via Three-Component Aza-Friedel-Crafts Reaction Catalyzed by Y(OTf).通过Y(OTf)催化的三组分氮杂傅克反应实现咪唑并[1,2-a]吡啶的C-烷基化反应
Molecules. 2024 Jul 24;29(15):3463. doi: 10.3390/molecules29153463.
7
Morpholine-modified Ru-based agents with multiple antibacterial mechanisms as metalloantibiotic candidates against infection.具有多种抗菌机制的吗啉修饰钌基制剂作为抗感染金属抗生素候选物。
RSC Adv. 2024 Jun 24;14(28):20130-20144. doi: 10.1039/d4ra02667e. eCollection 2024 Jun 18.
8
Copper-Catalyzed Three-Component Synthesis of Highly Substituted Morpholines.铜催化的多取代吗啉的三组分合成
Org Lett. 2024 Jun 7;26(22):4803-4807. doi: 10.1021/acs.orglett.4c01634. Epub 2024 May 29.
9
Expanding Complex Morpholines Using Systematic Chemical Diversity.利用系统化学多样性拓展复杂吗啡啉。
Org Lett. 2024 May 3;26(17):3493-3497. doi: 10.1021/acs.orglett.4c00528. Epub 2024 Mar 20.
10
Late-stage modification of bioactive compounds: Improving druggability through efficient molecular editing.生物活性化合物的后期修饰:通过高效分子编辑提高成药可能性。
Acta Pharm Sin B. 2024 Mar;14(3):1030-1076. doi: 10.1016/j.apsb.2023.11.021. Epub 2023 Nov 18.